CoChat

Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed/Refractory Myelofibrosis

Open access

The DOI matches its Crossref record.

Abstract

Background: Myelofibrosis (MF) patients (pts) who are relapsed or refractory (R/R) to JAK inhibitor (JAKi) treatment have a poor prognosis with a median overall survival of 11-13 months (Mascarenhas 2020; Palandri 2020). MF is characterized by excessive production of mouse double minute 2 (MDM2), a key negative regulator of the tumor suppressor protein p53, in CD34+ progenitor cells. Navtemadlin is a potent, selective, orally available MDM2 inhibitor that restores p53 function. Preclinically, navtemadlin drives apoptosis of TP53 wild-type (TP53WT) CD34+ MF cells through modulation of B cell lymphoma (BCL-2) family proteins. In a phase 2 study, navtemadlin showed clinically meaningful activity with disease-modifying potential in MF pts who were R/R to JAKi (Al-Ali 2020; Verstovsek 2022; Vachhani 2023). Aim: To evaluate the efficacy and safety of navtemadlin monotherapy vs best available therapy (BAT) in the phase 3 BOREAS study (NCT03662126). Methods: The BOREAS study enrolled TP53WT adults with primary or secondary MF who were R/R to JAKi treatment (JAKi-intolerant or JAKi-ineligible pts were excluded); ECOG 0-2, intermediate- (int-) or high-risk MF per DIPSS, platelets ≥50x109/L, and peripheral blasts <10%. Pts were randomized 2:1 to receive navtemadlin monotherapy 240 mg once-daily (Day 1-7/28-day cycle) or BAT (monotherapy or combinations: hydroxyurea, chemotherapy, IMiDs, and supportive care; JAKi were excluded). Pts were required to have a 28-day JAKi “wash-out” period prior to baseline MRI/CT. Crossover to navtemadlin was allowed at Week 24 or at time of disease progression. Anti-diarrhea prophylaxis was administered for the first two cycles and anti-nausea prophylaxis was given with every cycle for the seven days of navtemadlin treatment. The primary endpoint was rate of spleen volume reduction ≥35% (SVR35) at Week 24 by MRI/CT (blinded central review). The key secondary endpoint was the rate of total symptom score reduction ≥50% (TSS50) at Week 24 by MFSAF v4.0. Results: As of March 11, 2024 (enrollment stopped in August 2023), 183 pts were randomized (123 pts on navtemadlin and 60 pts on BAT; intention-to-treat population [ITT]) in 23 countries at 181 sites. Baseline characteristics were well balanced between the arms and included: int-1/int-2/high-risk MF per DIPSS (34%/50%/15%), median spleen volume of 2310 cm3, median TSS of 20.8, prior therapy range of 1-6 (99% had ruxolitinib [rux]), median time from initial MF diagnosis was 47.6 months, 34% of pts had platelets <100x109/L, 48% had a bone marrow fibrosis of grade 3, 70% had the JAK2V617F driver mutation, and 77% had ≥1 high molecular risk mutation (≥2 in 23%). At Week 24 (ITT), 15% (18/123) of pts vs 5% (3/60) achieved SVR35 (p=0.08) and 24% (30/123) vs 12% (7/60) achieved TSS50 (p=0.05) with navtemadlin vs BAT, respectively. Forty percent (24/60) of pts on BAT crossed over to navtemadlin. Marked reductions in disease biomarkers (ie, bone marrow fibrosis, driver mutation allele burden, and blood CD34+ progenitors) were greater with navtemadlin, suggesting potential disease modification. At the time of data cut, transformation to AML occurred in 1.6% (2/123) of pts on navtemadlin vs 3.3% (2/60) on BAT; all four pts were TP53WT. At a median follow-up of 10.7 months, the most common hematologic (heme) grade 3/4 treatment-emergent adverse events (TEAEs) were thrombocytopenia (37% vs 21%), anemia (29% vs 25%), and neutropenia (24% vs 12%) with navtemadlin vs BAT, respectively. Gastrointestinal (GI) grade 3/4 TEAEs were diarrhea (5% vs 2%), nausea (3% vs 0%), and vomiting (2% vs 0%) with navtemadlin vs BAT, respectively. Mean platelet and hemoglobin levels remained stable over the course of study treatment. Dose reductions and discontinuations for heme TEAEs were 26% and 3%, and for GI TEAEs were 8% and 0%. Conclusion: BOREAS is the first randomized, global phase 3 study conducted solely in MF pts R/R to JAKi to report results. In this phase 3 study, navtemadlin monotherapy was safe and effective, demonstrating clinically relevant efficacy with disease-modifying potential. The rate of SVR35 and TSS50 at Week 24 was three-fold and two-fold higher with navtemadlin vs BAT, validating the novel approach of MDM2 inhibition in pts with MF. Further studies of navtemadlin in MF are warranted, including as add-on therapy to rux treatment in JAKi-naive pts who have a suboptimal response to rux (POIESIS; NCT06479135).

Overview

Integrity signals

Registry

Crossref · 10.1182/blood-2024-201642

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Still being checked.

Cited by

See all 19

Metadata

Authors
Mascarenhas, J. O., Popov, V. M., Mohan, S., Özkurt, Z. N., Kiladjian, J.-J., Al-Ali, H. K., Perkins, A., Huang, Z., Qamoos, H., McGreivy, J., Rothbaum, W., Verstovsek, S., & Kaźmierczak, M.
Affiliations
  • Tisch Cancer Institute (US)
  • Spitalul Clinic Colentina (RO)
  • Vanderbilt Health (US)
  • Gazi University (TR)
  • Hôpital Saint-Louis (FR)
  • 6University Hospital Halle, Halle (Saale), Germany
  • The Alfred Hospital (AU)
  • Kartos Therapeutics, Inc. (United States) (US)
  • 8Kartos Therapeutics, Inc., Redwood City, CA
  • Poznan University of Medical Sciences (PL)
Venue
Blood
Published
2024-11-05
Volume
144
Issue
Supplement 1
Pages
1000-1000
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W4405044192
Cited by
17
References
0
Citations by year
2026: 10 · 2025: 7
Type
conference abstract
Language
en
Open access
Locations
Blood (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Keywords
MDM2 inhibitors, p53 restoration, wild-type p53, best available therapy, overall survival, progression-free survival, Bcl-2 family proteins, CD34+ cells, hydroxyurea, immunomodulators, diarrhea prevention, BOREAS

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed/Refractory Myelofibrosis. https://app.cochat.ai/papers/10.1182/blood-2024-201642
The paper
Mascarenhas, J. O., Popov, V. M., Mohan, S., Özkurt, Z. N., Kiladjian, J.-J., Al-Ali, H. K., Perkins, A., Huang, Z., Qamoos, H., McGreivy, J., Rothbaum, W., Verstovsek, S., & Kaźmierczak, M. (2024). Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed/Refractory Myelofibrosis. Blood. https://doi.org/10.1182/blood-2024-201642

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.